▲ S&P 500 +---% | ▲ Stock Advisor +---% Join The Motley Fool

Accessibility Log In Help

Daily Stock Gainers Daily Stock Losers Most Active Stocks

Daily Stock Gainers Daily Stock Losers Most Active Stocks

OncoCyte (NASDAQ: OCX)

$2.90

(3.6%)

$0.10

Price as of May 20, 2025, 3:54 p.m. ET

OncoCyte Return vs. S&P

	1 Year	5 Year	5 Year Annualized	Since IPO
OCX	+6.52%	-94.10%	-43.22%	-98%
S&P	+11.91%	+101.47%	+15.04%	+191%

OncoCyte Company Info

OncoCyte Corp. is a molecular diagnostics company, which engages in the development and commercialization of diagnostic tests for the detection of cancer, including molecular diagnostic services to pharmaceutical customers. Its products include DetermaRx and DetermaIO. The firm also offers pharmaceutical services like multi-analyte test development and clinical trial services. The company was founded in September 2009 and is headquartered in Alameda, CA.

News & Analysis

Featured Article

Why Oncocyte Shot 13% Higher Today

The announcement of a new share issue usually drives a stock's price down, after all.

Eric Volkman | Feb 5, 2021

Featured Article

Here's Why OncoCyte Is Giving Back Some Gains Today

A bit of profit taking after huge gains yesterday is pressuring the liquid biopsy developer.

Cory Renauer | Jan 30, 2019

Valuation

Earnings Transcripts

OncoCyte Corporation (OCX) Q1 2019 Earnings Call Transcript

OCX earnings call for the period ending March 31, 2019.

Motley Fool Transcription | May 14, 2019

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services